W.‐K. Hofmann - Concepedia

Author

W.‐K. Hofmann

Also Known As

Hofmann, W. -K., Hofmann, W.-K., M. Milovanovic, W Hofmann, W K Hofmann, W-K Hofmann, W. Hofmann, W. K. Hofmann, W.-K. Hofmann, W.‐K. Hofmann

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Heidelberg University University Hospital Heidelberg University Medical Centre Mannheim Munich Leukemia Laboratory (Germany)University Medical Center Freiburg

About

W.‐K. Hofmann is an author at Heidelberg University specializing in medicine, hematology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	1.8K
2	Cell Biology	9	9	1.1K
3	Health Sciences	4	4	499
4	Engineering	1	1	135
5	Biostatistics	1	1	53

W.‐K. Hofmann

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann, Leukemia Hematological MalignancyChronic Myeloid LeukemiaHealth SciencesMedicineHematology	2012	416
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis Mohamad Jawhar, Juliana Schwaab, Susanne Schnittger, Leukemia Additional MutationsMast Cell DisorderSystemic MastocytosisPathogenesisImmunology	2015	218
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event Mohamad Jawhar, Juliana Schwaab, Susanne Schnittger, Leukemia ImmunogeneticsMedicineMast Cell DisorderImmunologyMyeloid Neoplasia	2015	149
Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Takayuki Ikezoe, Miller Cw, Seiji Kawano, PubMed PathologyCancer BiologyTumor BiologyCancer Cell BiologyHuman Malignancies	2001	140
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib Benjamin Hanfstein, Valeria Shlyakhto, Michael Lauseker, Leukemia Chronic PhaseHematological MalignancyChronic Myeloid LeukemiaOncologyOptimized Predictor	2014	135
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia Vikas Madan, Pavithra Shyamsunder, Lin Han, Leukemia	2016	134
The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. Reinhard Schwartz‐Albiez, B Dörken, W.‐K. Hofmann, The Journal of Immunology Adaptive Immune SystemImmunologyGlycobiologyImmunophenotypingBlood Cell	1988	126
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib B. Hanfstein, Michael Lauseker, R Hehlmann, Haematologica	2014	118
Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study Tobias Boch, Oliver A. Cornely, Jörg Janne Vehreschild, Clinical Microbiology and Infection Diagnostic MycologyMolecular Diagnostic TechniquesAntifungal AgentAntifungal AgentsAspergillus Pcr	2016	103
Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies Mark Reinwald, Michael Hummel, Werner Heinz, Journal of Antimicrobial Chemotherapy	2012	94

Page 1